Consortium for Clinical Research and Innovation, Singapore

Consortium for Clinical Research and Innovation, Singapore (CRIS) is a Singapore government-linked clinical research and translational innovation organization that coordinates national platforms supporting clinical trials, health innovation, cell therapy, precision health, oncology, cardiovascular research, and healthcare AI. Established in 2020 and officially launched in 2022, CRIS operates as a subsidiary of MOH Holdings and serves as an umbrella organization for multiple national research and service initiatives. Rather than operating as a therapeutics developer with a conventional drug pipeline, CRIS provides infrastructure, strategy, capability building, partnerships, and commercialization support for Singapore's clinical and translational research ecosystem. Its business units include the Singapore Clinical Research Institute, National Health Innovation Centre Singapore, Advanced Cell Therapy and Research Institute Singapore, Precision Health Research Singapore, Singapore Translational Cancer Consortium, Cardiovascular Disease National Collaborative Enterprise, and the SIMFONI AI initiative. CRIS is relevant to biotech and healthcare analysts because it sits at the interface of clinical development, translational medicine, health-system innovation, and public-sector biomedical capability building in Singapore.